Expression of CD44, PCNA and E-cadherin in Pterygium Tissue

Not yet recruiting

• Conditions: Pterygium
• Interventions: Other: Expression of CD44, E-cadherin and PCNA

• Registration Number: NCT06042296
• Lead Sponsor: Balikesir University

Brief Summary

Purpose: Pterygium is a common ocular surface disease defined by fibrovascular conjunctival growth extending onto the cornea. Its pathogenesis remains unclear. In severe cases, it may extend into the central cornea, inducing irregular corneal astigmatism and causing loss of vision. CD44( phagocytic glycoprotein-1 ) is involved in the organization of certain cellular processes, for instance, cell adhesion, division, and migration, by binding with its main ligand, hyaluronic acid. Proliferating cell nuclear antigen (PCNA) is a proliferation marker in the nucleus. E-cadherin is a calcium-dependent transmembrane glycoprotein that plays a significant role in the protection of tissue integrity and cell-to-cell adhesion. This study aimed to determine the role of CD44, proliferating cell nuclear antigen (PCNA), and E-cadherin in pterygium formation and recurrence.

Detailed Description

Methods:60 patients with pterygium will be enrolled in the study and conjunctival samples will be collected from 30 patients to form the control group. CD44, PCNA and E-cadherin expressions in surgically removed pterygium will be compared with tissue samples from normal control group.

IBM SPSS (statistical software) version 26.0 will be used for statistical analyses.

Study Timeline

• Status Verified: 2023-09
• Study First Submitted: 2023-09-10
• Study First Submitted QC: 2023-09-15
• Last Update Submitted: 2023-09-15
• Study First Posted: 2023-09-18
• Last Update Posted: 2023-09-18
• Study Start: 2023-10
• Primary Completion: 2023-12
• Study Completion: 2024-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

patient with pterygium -

Exclusion Criteria

patient with pseudopterygium

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
group 2 primary pterygia	Expression of CD44, E-cadherin and PCNA	primary pterygia samples from 30 patients
control group	Expression of CD44, E-cadherin and PCNA	group 1 -control group normal conjunctiva from 30 patients
group 3 recurrent pterygia	Expression of CD44, E-cadherin and PCNA	recurrent pterygia samples from 30 patients

Primary Outcome Measures

Name	Time	Method
Immunohistochemistry	up to three weeks after pterygium surgery	Thin sections will be taken from paraffin embedded tissue samples and placed on barcode glass slides After deparaffinization and rehydration, the sections will be subjected to histopathological evaluation using hematoxylin and eosin staining.We use primary antibodies against CD44 (1:50 dilution) and E-cadherin (1:200 dilution), and a human monoclonal antibody against PCNA (1:100 dilution) for antigen retrieval

Trial Locations

Locations (1)

Hümeyra Yildirim; 🇹🇷 Balıkesir, Turkey